Among all integrins, ITGA3 emerged as a promising single-gene biomarker with clinical relevance, specifically associated with resistance to chemotherapy and immunotherapy in pancreatic cancer owing to its purity-independent characteristics. This evidence concerns the gene ITGA3 and pancreatic neoplasm.